One thing to look for in evaluating the extent to which we can return to normal: development of antivirals. I’m fairly confident that we’ll be seeing some good ones. Add that to existing improvements—the vaccines, rapid home tests, PCR tests that check for covid, flu and RSV (!!!) and we could very well be indistinguishable from normal by fall. Speaking of RSV, Moderna is currently in late phase trials for an RSV vaccine. I’m guessing we’ll eventually have an all-in-one vaccine for common respiratory pathogens, using the mRNA platform.
Huge if true! Do you just mean that incentives for antiviral production are now better because of COVID or that you know of specific reasons to think good ones will be produced?
One thing to look for in evaluating the extent to which we can return to normal: development of antivirals. I’m fairly confident that we’ll be seeing some good ones. Add that to existing improvements—the vaccines, rapid home tests, PCR tests that check for covid, flu and RSV (!!!) and we could very well be indistinguishable from normal by fall. Speaking of RSV, Moderna is currently in late phase trials for an RSV vaccine. I’m guessing we’ll eventually have an all-in-one vaccine for common respiratory pathogens, using the mRNA platform.
Huge if true! Do you just mean that incentives for antiviral production are now better because of COVID or that you know of specific reasons to think good ones will be produced?